2016
DOI: 10.1016/j.jval.2016.09.2094
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Objectives: Soft tissue sarcomas (STSs) are cancers originating in connective tissue; in 50% of cases, patients initially present with or develop advanced or metastatic disease. Prognosis is poor with standard-of-care, anthracycline-containing systemic therapy; median overall survival (OS) is approximately 1 year. A recent phase 2 trial investigated olaratumab, a human anti-platelet-derived growth factor receptor alpha monoclonal antibody, in combination with doxorubicin, for treatment of advanced STS (aSTS). … Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles